We found that VD3-GNP treatment significantly lowers the protein expression levels of YAP/TAZ cascades, as well as the p-YAP (Ser 127) levels in breast cancer cells (MCF-7 and MDA-MB-231 cell lines, Figure 9A–D), which highlights the possible modulation of cross-talk between the Hippo and PI3K/mTOR/AKT pathways by VD3, even at a very low dosage (nM range) [64]. This evidence concerns the gene AKT1 and breast cancer.